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OBJECTIVES We sought to demonstrate that brachytherapy reduces coronary spasm in refractory and
highly symptomatic variant angina.
BACKGROUND In some patients with variant angina due to extensive vasoconstriction, intensive drug therapy
fails to sufficiently relieve symptoms.
METHODS In 18 patients with frequent angina episodes despite triple anti-anginal therapy, coronary
spasm was induced by intracoronary acetylcholine (ACh) infusion. Five patients had spasm in
a second vessel. Intracoronary radiation (20 Gy) was applied to vasospastic segments using a
beta-emitting (32P) wire source centered within a Galileo balloon. Parameters of vessel
function before and after brachytherapy were investigated.
RESULTS Before brachytherapy, artery diameters decreased (p  0.0001) from 2.8  0.4 mm to 1.0 
0.4 mm for the first vessels and from 3.1  0.3 mm to 1.0  0.2 mm for the second vessels.
After brachytherapy (143  106 and 80  52 days for first and second vessels, respectively),
ACh-induced vasoconstriction was significantly reduced. The ACh-induced changes in artery
diameter before and after brachytherapy were 1.5  0.5 mm and 0.5  0.3 mm (p 
0.0001) for the first vessels and 1.4  0.3 mm and 0.4  0.2 mm (p  0.01) for the
second vessels, respectively. In non-irradiated spastic vessels, ACh-induced vasoconstriction
remained unchanged (e.g.,1.7 0.6 mm,1.6 0.3 mm, and1.5 0.5 mm for second
vessels, at first investigation, first follow-up, and immediately before brachytherapy, respec-
tively). Angina frequency decreased from 15.6  6.0 to 2.2  2.4 angina episodes/week (p 
0.001) in treated patients.
CONCLUSIONS Brachytherapy is a potential therapy in patients with highly symptomatic variant
angina. (J Am Coll Cardiol 2004;44:1415–9) © 2004 by the American College of
Cardiology FoundationM
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tn most patients with variant angina, spasm occurs at the
ite of atheromatous plaque, although the degree of stenosis
ue to plaque is moderate and commonly 30% of the
ormal segment diameter (1). To document variant angina,
provocative test by infusion of acetylcholine (ACh) into
oronary arteries is sometimes necessary (2). Most patients
an be medically treated with vasodilating drugs. However,
ome are highly symptomatic and drug-resistant, and stent-
ng has been used (3).
Although application of brachytherapy produces an im-
ediate increase of vasoconstriction and spasms (4,5), a loss
f vasomotion some weeks after brachytherapy occurs (6).
his effect renders brachytherapy as a potential therapeutic
odality for patients with highly symptomatic variant
ngina. We reported an index case of a post-brachytherapy
eduction of angina in a patient with coronary vasospasm
7). This patient died subsequently, and autopsy revealed
oronary thrombosis of the irradiated left anterior descend-
ng (LAD) coronary artery and untreated intermediate
rtery. Nevertheless, given the significant effect of brachy-
herapy in relieving angina, we cautiously further investi-
ated the potential of brachytherapy in refractory coronary
pasm.
From the Divisions of *Cardiology and †Radiotherapy, Kantonsspital Luzern,
uzern; and the ‡Department of Research, Kantonsspital Basel, Basel, Switzerland.
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atients. Eighteen patients with frequent angina and re-
ractoriness to intensive anti-ischemic therapy were in-
luded. Seven and four patients had ST-segment elevations
nd depressions, respectively, on the electrocardiogram dur-
ng chest pain at rest. Patients underwent initial diagnostic
ork-up to exclude coronary artery disease and document
asoconstrictive responsiveness to ACh. If similar ACh-
esponsiveness was documented within eight weeks (inclu-
ion criteria), investigation was repeated and brachytherapy
pplied to the dominant vasospastic vessel. The local ethical
ommittee approved the protocol. Patients gave written,
nformed consent. Three months before brachytherapy and
or the study duration, patients reported weekly anginal
pisode occurrence and nitrate use. Relevant patient char-
cteristics, risk factors, and drug therapies are presented in
able 1.
No patient had angiographically visible plaque. Acetyl-
holine was infused (10 mol/l, constant) into coronary
rteries, and vasospasms were quantitated by quantitative
oronary angiography if vasoconstriction 50% diameter
tenosis occurred (8). Vasospastic vessel locations were
dentified anatomically in a predefined projection, which
as repeated at follow-up investigations. A prophylactic
emporary pacing lead was placed into the right ventricular
pex at a backup rate of 40 beats/min. Nitroglycerin was
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Vasospasms and Brachytherapy October 6, 2004:1415–9njected (100 to 200 g bolus) into the coronary artery to
elieve spasm. Coronary flow and its response to intracoro-
ary injection of adenosine (30 g bolus) and nitroglycerin
200 g bolus) were assessed. Average peak velocities,
oronary flow reserve (CFR), flow acceleration rate (dv/
t), and flow deceleration rate (dv/dt) were determined
ith a Cardiometrics Doppler guidewire (9). To assess
unctional vessel distensibility, adenosine-induced changes
n acceleration and deceleration rate of flow velocities
dv/dt and dv/dt, respectively) were determined.
Vessel response to ACh by length was inhomogeneous.
essel areas with the greatest spasm (50% diameter
tenosis) were selected for radiation. The entire length of
his region was irradiated. We applied a 32- or 52-mm-long
entering balloon if the length of spasm was 25 mm or
25 mm, respectively. Irradiated vessels included the LAD,
ircumflex artery, and right coronary artery. Brachytherapy
20 Gy, based on non-constricted vessel diameter) was
pplied through a beta-emitting (32P) wire source centered
ithin Galileo balloons (Guidant Corp., Santa Clara, Cal-
fornia) (10). Radiation was targeted 1 mm beyond the
essel wall (11) and over the entire length (38  12 mm) of
he affected segment. In three patients in whom the affected
rea was longer than 52 mm, a second more proximal part
Abbreviations and Acronyms
ACh  acetylcholine
CFR  coronary flow reserve
dv/dt  flow acceleration rate
dv/dt  flow deceleration rate
LAD  left anterior descending
able 1. Patient Description
ender (M/F) 15/3
ge (yrs) 60  9.4 (43–72)
eight (cm) 171  8 (151–181)
eight (kg) 78  11 (60–104)
ardiovascular risk factors
Hypertension 11
Dyslipidemia 15
Diabetes 2
Current/former smokers 5/5
Previous myocardial infarction 4
ndication for coronary angiography
ST-segment changes on exercise 5
Angina at rest 6
Vasospastic infarction 3
Unstable angina 4
Before
Brachytherapy
At Final
Follow-Up
pisodes and pharmacotherapies
Anginal episodes/week 15.6  6.0 2.2  2.4
Amlodipine (mg/day) 7.7 4.3 1.8 2.0
Nebivolol (mg/day) 6.4 3.2 1.9 1.6
Molsidomine (mg/day) 12.0 7.5 0
Nitrate use/week 8.5  3.6 1.3 1.4sata are presented as the mean value  SD (range) or number of patients.f the vessel was treated after pullback of the centering
alloon.
Patients were re-investigated 143  106 days after the
rst brachytherapy. To assess putative changes over time,
ollow-up after intracoronary irradiation was carried out
etween weeks 5 to 8, 10 to 3, 7 to 20, 35 to 38, and 80 to
3 (3, 4, 5, 3, and 3 patients, respectively). Vessel function
as documented by intracoronary administration of ACh
nd flow measurements repeated. Five patients had insuffi-
ient improvement of symptoms because of vasospasms in a
econd artery. Vasospasm in these arteries was identified
uring pre-diagnostic work-up, but a decision not to irra-
iate these arteries at the first brachytherapy session was
ade on the basis of: 1) uncertainty of clinical outcome of
he first brachytherapy; and 2) risk of late thrombosis. In
hese, brachytherapy was staged. These patients served as an
mportant control group, as parameters for the second
pastic vessels in the non-irradiated state were assessed on
hree occasions: initial diagnostic work-up, first brachyther-
py, and first follow-up (136  39 days) after irradiation of
he first vessel. Invasive follow-up of the second vessels was
arried out after 80  52 days (between weeks 4 to 7, 9 to
2, and 16 to 19 in 1, 2, and 2 patients, respectively).
After brachytherapy, patients were treated with clopi-
ogrel (75 mg/day) for one year and acetylsalicylic acid
100 mg/day) life-long to prevent thrombosis. Patients
ere followed clinically each month for one year, and
rug therapies were individually reduced according to
ymptoms.
tatistical analysis. Results are expressed as the mean
alue  SD. The Student t test (two-tailed, paired) was
pplied for statistical evaluation.
ESULTS
he indications for coronary angiography are shown in
able 1. Spasm in response to ACh infusion was docu-
ented at the initial diagnostic work-up (“reference
essel diameters”) (Table 2). Parameters of the second
essels in their non-irradiated state, repeatedly measured,
emained constant (Tables 2 and 3, Figs. 1 and 2). The
ffects of brachytherapy were consistent for all patients
nd for both spastic vessels and independent of the
ollow-up period.
Table 2 summarizes invasive parameters. Before brachy-
herapy, affected vessels exhibited vasoconstriction to ACh.
nhanced acute vasoconstriction occurred immediately after
rachytherapy, and nitroglycerin (mean of 400 g [range
00 to 1,200 g]) was required to resolve spasms. At
ollow-up after brachytherapy, ACh-induced vasoconstric-
ion at the brachytherapy location was abrogated, while
asospastic vessels in the non-irradiated state maintained
he constrictor response to ACh (Table 2, Fig. 1). Ejection
raction, left ventricular end-diastolic pressure, and respon-
iveness to nitrate were unaffected (Table 2).
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October 6, 2004:1415–9 Vasospasms and BrachytherapyTable 3 summarizes flow parameters. The CFR was not
ffected. After brachytherapy, baseline dv/dt and dv/dt
ere increased, whereas dv/dt and dv/dt responses to
denosine tended to decrease. Evaluation of the difference
n flow measurements before and after brachytherapy re-
ealed an alteration in the adenosine-induced change in
oth dv/dt and dv/dt (Fig. 2). Vasospastic vessels in
heir non-irradiated state retain their vasomotor response to
denosine (Table 3, Fig. 2).
Molsidomine was stopped at hospital discharge after the
rst brachytherapy in all patients, and other anti-anginal
rugs were reduced at follow-up (Table 1). By the 12-
onth final follow-up, patients were experiencing less
nginal episodes per week (Table 1, Fig. 3).
Two adverse events were associated with the protocols.
ne patient suffered a hematoma at the puncture site on the
ccasion of invasive follow-up and required blood transfu-
ion. A second patient developed a significant stenosis of the
able 3. Effects of Brachytherapy on Flow Parameters
Pre-Therapy Investigation
First
Vessel
(n  18)
Second
Vessel
(n  5)
FR 2.7  0.9 2.9  0.6
aseline
Acceleration (dv/dt) 238.6 91.9 312.3  69.4
Deceleration (dv/dt) 104.0 36.0 104.4  27.2
denosine
Acceleration (dv/dt) 369.7 116.4 459.6  96.5
Deceleration (dv/dt) 262.2 70.8 262.2  57.4
p  0.05, †p  0.01, and ‡p  0.001 indicate the difference before and after brach
able 2. Effects of Brachytherapy on Invasively Determined Para
Reference Diameters
(Initial Diagnostic
Work-Up)
Pre-Ther
Investiga
First
Vessel
(n  18)
Second
Vessel
(n  5)
First
Vessel
(n  18)
ollow-up (days)
jection fraction (%) 61  11
VEDP 18  6
essels irradiated
LAD
Cx
RCA
iameter of vessels
(mm)
Baseline 2.9 0.4 2.3  0.4 2.8  0.4 3
Acetylcholine 1.2 0.3 1.2  0.2 1.0  0.4 1
Nitrate 3.0 0.4 2.8  0.4 3.0  0.5 3
essel diameters after acetylcholine administration differ before and after brachyther
Cx  circumflex artery; LAD  left anterior descending coronary artery; LVEDCFR  coronary flow reserve; dv/dt  flow acceleration rate; dv/dt  flow decelereft main artery between first brachytherapy of the LAD and
nvasive follow-up.
ISCUSSION
his is the first clinical study on brachytherapy in drug-
esistant vasospastic angina and ACh-induced coronary
pasms. Clinical follow-up demonstrated major symptom
elief. A brachytherapy-associated reduction of angina was
ccompanied by a loss of vasoconstriction to ACh. Brachy-
herapy reduced vasomotor response to adenosine, which
ay be due to increased baseline dv/dt and dv/dt and
eflective of decreased vessel distensibility. Anti-anginal
herapy can be reduced after brachytherapy.
Follow-up periods varied (21 to 463 days), but the results
ere consistent, suggesting that vessel wall response to
rachytherapy takes place early and is persistent. This is
First Follow-Up Second Follow-Up
First Vessel After
Brachytherapy
(n  18)
Nonirradiated
Second Vessel
(n  5)
Second Vessel After
Brachytherapy
(n  5)
2.5 0.8 2.9  0.6 2.2  0.3
283.0 74.3† 305.1  61.4 280  139.4
203.3 67.6‡ 105.3  25.3 230.0  28.1†
295.5 73.6 460.5  76.5 278.0  116.7
214.0 69.7* 252.1  48.2 225.6  30.2
py. Data are presented as the mean value  SD.
rs of Vessel Function
First Follow-Up Second Follow-Up
nd
el
5)
First Vessel After
Brachytherapy
(n  18)
Nonirradiated
Second Vessel
(n  5)
Second Vessel After
Brachytherapy
(n  5)
143 106 136  39 80  52
4 61  12 68  6 ND
2.2 13  2 13  3 ND
10 1
4 3
4 1
0.3 2.9  0.4 3.0  0.2 2.8  0.3
0.2 2.5  0.4* 1.1  0.2 2.3  0.3*
0.3 3.0  0.4 3.3  0.2 2.8  0.3
 0.0001). Data are presented as the mean value  SD.
eft ventricular end-diastolic pressure; RCA  right coronary artery.ytheramete
apy
tion
Seco
Vess
(n 
66 
15 
.1 
.0 
.2 
apy (*p
P  lation rate.
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Vasospasms and Brachytherapy October 6, 2004:1415–9onsistent with the reduction in angina within hours of
rachytherapy and the fact that molsidomine administration
ould be halted at discharge (one day after the procedure).
We caution that brachytherapy can be associated with
dverse events. Brachytherapy is known to be associated
ith a risk of late thrombosis. However, our patients were
reated with clopidogrel for 12 months and continuous
cetylsalicylic acid. One patient developed progression of a
eft main plaque narrowing (75%) within 315 days after
rachytherapy of the LAD. This could result from progres-
ion of native disease or stimulatory effects of irradiation.
Effects of brachytherapy on coronary artery tone and
asomotion are poorly understood. Immediately after
rachytherapy, extensive vasoconstriction occurs, as shown
n this study and others (4,5), and intracoronary nitroglyc-
rin is necessary. Endothelium-dependent vasomotion of
oronary segments treated with balloon angioplasty was
eported to normalize at six months after brachytherapy (8).
his study investigated patients with coronary artery dis-
ase, while herein no patient presented with coronary
esions. Our results suggest additional endothelium-
ndependent effects of brachytherapy.
tudy limitations. A larger study of less symptomatic
atients is needed to assess the clinical impact of
ntracoronary irradiation for variant angina. The study did
ot address the cellular mechanism of action of
igure 1. Brachytherapy reduces acetylcholine (ACh)-induced vasocon-
triction. Individual vessel diameter changes (with median values) after
nfusion with ACh before and after brachytherapy. Circles  first vessel
nd squares  second vessel before (open circles and open squares) and
t follow-up after brachytherapy (solid circles and solid squares); second
essel in non-irradiated states at first investigation (open triangles) and
ollow-up after brachytherapy of first vessel (solid triangles). p indicates
ffect of brachytherapy.rachytherapy. conclusions. Brachytherapy appears to be a potential ther-
py in preventing the recurrence of vasospasm in patients
ith refractory and highly symptomatic variant angina.
igure 2. Brachytherapy reduces adenosine-induced changes in accelera-
ion and deceleration time of flow velocities. Individual adenosine-induced
hanges (with median values) in acceleration (dv/dt; upper panel) and
eceleration (dv/dt; lower panel) flow velocities before and after
rachytherapy. Circles  first vessel and squares  second vessel before
open circles and open squares) and at follow-up after brachytherapy
solid circles and solid squares). Second vessel in non-irradiated states at
oth the first investigation (open triangles) and follow-up after brachy-
herapy of first vessel (solid triangles). p indicates effect of brachytherapy.
igure 3. Brachytherapy reduces the frequency of anginal episodes. Weekly
requency of anginal episodes for each patient before brachytherapy (open
ircles) and at follow-up (solid circles).
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